• Shuxin Zhen, Guiping Wang, Xiaoli Li, Jing Yang, Jiaxin Yu, and Yucong Wang.
• Department of Internal Medicine, Tangshan Gongren Hospital, Tangshan, Hebei, China.
• Medicine (Baltimore). 2024 Jan 12; 103 (2): e36849e36849.

AbstractUnusual blood clots can cause serious health problems, such as lung embolism, stroke, and heart attack. Inhibiting thrombin activity was adopted as an effective strategy for preventing blood clots. In this study, we explored computational-based method for designing peptide inhibitors of human thrombin therapeutic peptides to prevent platelet aggregation. The random peptides and their 3-dimentional structures were generated to build a virtual peptide library. The generated peptides were docked into the binding pocket of human thrombin. The designed strong binding peptides were aligned with the native binder by comparative study, and we showed the top 5 peptide binders display strong binding affinity against human thrombin. The 5 peptides were synthesized and validated their inhibitory activity. Our result showed the 5-mer peptide AEGYA, EVVNQ, and FASRW with inhibitory activity against thrombin, range from 0.53 to 4.35 μM. In vitro anti-platelet aggregation assay was carried out, suggesting the 3 peptides can inhibit the platelet aggregation induced by thrombin. This study showed computer-aided peptide inhibitor design can be a robust method for finding potential binders for thrombin, which provided solutions for anticoagulation.Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.

26 keywords...

hide…